Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Einstein

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2024
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK TrialDavid J Einstein, Meredith M Regan, Julia S Stevens, et al.
Journal of Oncology Practice|June 1, 2017
Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based TherapiesDavid J Einstein, Susan DeSanto-Madeya, Matthew Gregas, et al.
JCO Precision Oncology|January 20, 2022
Assessment of Molecular Remission in Oligometastatic Esophageal Cancer With a Personalized Circulating Tumor DNA AssayDavid J Einstein, Nathan Liang, Meenakshi Malhotra, et al.
Molecular Cancer Therapeutics|October 3, 2025
Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancerSheng-Yu Ku, Nishat Manzar, Maria Mica Garcia, et al.
The Urologic Clinics of North America|October 3, 2020
The Potential Role for Immunotherapy in Biochemically Recurrent Prostate CancerMarijo Bilusic, David J Einstein, Fatima H Karzai, et al.
Urology|February 22, 2019
Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate CancerDavid J Einstein, Dattatraya Patil, Jonathan Chipman, et al.
Molecular Cancer Therapeutics|June 19, 2024
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate CancerMannan Nouri, Andreas Varkaris, Maya Ridinger, et al.
International Journal of Radiation Oncology, Biology, Physics|April 18, 2026
Treatment-Free Survival: A Novel Endpoint in Trials of Stereotactic Body Radiation With or Without Systemic TherapyDavid J Einstein, Ronald C Chen, Karen E Hoffman, et al.
JCO Precision Oncology|September 27, 2021
Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary TumorsDavid J Einstein, Seiji Arai, Carla Calagua, et al.
Cancer Letters|September 16, 2018
Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancerJoshua W Russo, Xiaming Liu, Huihui Ye, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2024
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK TrialDavid J Einstein, Meredith M Regan, Julia S Stevens, et al.
Journal of Oncology Practice|June 1, 2017
Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based TherapiesDavid J Einstein, Susan DeSanto-Madeya, Matthew Gregas, et al.
JCO Precision Oncology|January 20, 2022
Assessment of Molecular Remission in Oligometastatic Esophageal Cancer With a Personalized Circulating Tumor DNA AssayDavid J Einstein, Nathan Liang, Meenakshi Malhotra, et al.
Molecular Cancer Therapeutics|October 3, 2025
Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancerSheng-Yu Ku, Nishat Manzar, Maria Mica Garcia, et al.
The Urologic Clinics of North America|October 3, 2020
The Potential Role for Immunotherapy in Biochemically Recurrent Prostate CancerMarijo Bilusic, David J Einstein, Fatima H Karzai, et al.
Urology|February 22, 2019
Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate CancerDavid J Einstein, Dattatraya Patil, Jonathan Chipman, et al.
Molecular Cancer Therapeutics|June 19, 2024
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate CancerMannan Nouri, Andreas Varkaris, Maya Ridinger, et al.
International Journal of Radiation Oncology, Biology, Physics|April 18, 2026
Treatment-Free Survival: A Novel Endpoint in Trials of Stereotactic Body Radiation With or Without Systemic TherapyDavid J Einstein, Ronald C Chen, Karen E Hoffman, et al.
JCO Precision Oncology|September 27, 2021
Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary TumorsDavid J Einstein, Seiji Arai, Carla Calagua, et al.
Cancer Letters|September 16, 2018
Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancerJoshua W Russo, Xiaming Liu, Huihui Ye, et al.
Pageof 6